[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Personalis Inc (PSNL)

Personalis Inc (PSNL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,279,691
  • Shares Outstanding, K 104,721
  • Annual Sales, $ 69,650 K
  • Annual Income, $ -81,270 K
  • EBIT $ -103 M
  • EBITDA $ -96 M
  • 60-Month Beta 2.24
  • Price/Sales 18.75
  • Price/Cash Flow N/A
  • Price/Book 5.52

Options Overview Details

View History
  • Implied Volatility 54.64% (-3.73%)
  • Historical Volatility 80.87%
  • IV Percentile 1%
  • IV Rank 2.98%
  • IV High 494.16% on 03/30/26
  • IV Low 41.14% on 07/22/26
  • Expected Move (DTE 28) 1.10 (8.90%)
  • Put/Call Vol Ratio 11.00
  • Today's Volume 48
  • Volume Avg (30-Day) 2,199
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 16,841
  • Open Int (30-Day) 19,012
  • Expected Range 11.22 to 13.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 1
  • High Estimate $-0.25
  • Low Estimate $-0.25
  • Prior Year $-0.23
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.65 +5.62%
on 06/25/26
16.39 -24.95%
on 07/17/26
+0.94 (+8.27%)
since 06/24/26
3-Month
4.95 +148.23%
on 04/29/26
16.39 -24.95%
on 07/17/26
+6.20 (+101.64%)
since 04/24/26
52-Week
3.84 +220.31%
on 08/06/25
16.39 -24.95%
on 07/17/26
+5.59 (+83.31%)
since 07/24/25

Most Recent Stories

More News
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Personalis ,...

PSNL : 12.14 (-0.65%)
TEM : 44.04 (-4.28%)
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

PSNL : 12.14 (-0.65%)
ATAI : 7.18 (+0.14%)
LXP : 60.91 (+0.15%)
DSGR : 34.51 (+0.01%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL)

NEW YORK , July 21, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

PSNL : 12.14 (-0.65%)
Tempus AI to Acquire Personalis in $1.5 Billion Deal to Expand Precision Oncology Platform

Tempus AI ($TEM) has agreed to acquire Personalis ($PSNL) in an all-stock transaction valued at approximately $1.5 billion in enterprise value, expanding its capabilities in minimal residual disease (MRD)...

PSNL : 12.14 (-0.65%)
TEM : 44.04 (-4.28%)
PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...

PSNL : 12.14 (-0.65%)
Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE , July 20, 2026 /PRNewswire/ -- Ademi LLP is investigating Personalis (NASDAQ: PSNL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

PSNL : 12.14 (-0.65%)
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth ...

PSNL : 12.14 (-0.65%)
TEM : 44.04 (-4.28%)
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth ...

PSNL : 12.14 (-0.65%)
TEM : 44.04 (-4.28%)
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

Regulatory milestone for the NeXT Personal® Dx test enables clinical use of Personalis’ ultrasensitive MRD detection in Great Britain

PSNL : 12.14 (-0.65%)
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Regulatory milestone for specimen collection kits enables global deployment of Personalis’ ultrasensitive MRD detection (Next Personal®) for drug development programs

PSNL : 12.14 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.

See More

Key Turning Points

3rd Resistance Point 13.50
2nd Resistance Point 13.18
1st Resistance Point 12.70
Last Price 12.14
1st Support Level 11.91
2nd Support Level 11.59
3rd Support Level 11.11

See More

52-Week High 16.39
Last Price 12.14
Fibonacci 61.8% 11.60
Fibonacci 50% 10.11
Fibonacci 38.2% 8.63
52-Week Low 3.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.